Objective: To determine immunity to tetanus and diphtheria in the Australian population.
Design and setting: Analysis, using double antigen enzyme immunoassays, of a representative sample of sera (1950 samples tested for diphtheria and 2884 for tetanus) collected opportunistically from Australian laboratories between July 1996 and May 1999.
Main outcome measure: Immunity to diphtheria and tetanus, defined as negative (susceptible) when the antitoxin level was < 0.01 IU/mL, positive (immune) when it was ≥ 0.1 IU/mL, and low positive (partially immune) when it was in the range 0.01–< 0.1 IU/mL.
Results: About 99% of children aged 5–9 years had diphtheria and tetanus antitoxin levels ≥ 0.01 IU/mL (immune or partially immune). Antitoxin levels declined with age and generally more markedly for diphtheria than tetanus. For subjects aged 50 years and over, less than 60% were immune or partially immune to diphtheria and less than 75% to tetanus. Men and women had similar diphtheria antitoxin levels, while women had lower levels of tetanus antitoxin compared with men of the same age, with the difference being most marked in the age group ≥ 70 years (37% v 60%; P < 0.001).
Conclusions: Immunity in children appears to be good, but adults, especially older people, may not be adequately protected. Recent changes to the Australian Standard Vaccination Schedule should improve immunity in cohorts now aged < 50 years. However, additional efforts are required to protect those over 50 years (especially travellers), who are most susceptible.
- 1. Patel M, Morey F, Butcher A, et al. The frequent isolation of toxigenic and non-toxigenic Corynebacterium diphtheriae at Alice Springs Hospital. Commun Dis Intell 1994; 18: 310-311.
- 2. Vitek CR, Wharton M. Diphtheria in the former Soviet Union: reemergence of a pandemic disease. Emerg Infect Dis 1998; 4: 539-550.
- 3. Welty T, La Fromboise C, Dixon J, et al. Toxigenic Corynebacterium diphtheriae — Northern Plains Indian Community, August-October 1996. MMWR Morb Mortal Wkly Rep 1997; 46: 506-510.
- 4. Diphtheria cases notified in the European Union [Editorial Committee]. EuroSurveillance 1997; 2: 63-64.
- 5. Edmunds WJ, Pebody RG, Aggerback H, et al. The sero-epidemiology of diphtheria in Western Europe. ESEN Project. European Sero-Epidemiology Network. Epidemiol Infect 2000; 125: 113-125. (Erratum in: Epidemiol Infect 2001; 126: 331.)
- 6. McQuillan GM, Kruszon-Moran D, Deforest A, et al. Serologic immunity to diphtheria and tetanus in the United States. Ann Intern Med 2002; 136: 660-666.
- 7. Turnbull FM, Heath TC, Jalaludin BB, et al. A randomized trial of two acellular pertussis vaccines (dTpa and pa) and a licensed diphtheria-tetanus vaccine (Td) in adults. Vaccine 2000; 19: 628-636.
- 8. Gidding HF, Burgess MA, Kempe AE. A short history of vaccination in Australia. Med J Aust 2001; 174: 37-40.
- 9. Brotherton J, McIntyre P, Puech M, et al. Vaccine preventable diseases and vaccination coverage in Australia 2001 to 2002. Commun Dis Intell 2004; 28 Suppl 2: vii-S116.
- 10. Heath TC, Smith W, Capon A, et al. Tetanus immunity in an older Australian population. Med J Aust 1996; 164: 593-596.
- 11. Gilbert GL, Escott RG, Gidding HF, et al. Impact of the Australian Measles Control Campaign on immunity to measles and rubella. Epidemiol Infect 2001; 127: 297-303.
- 12. AusStats. Population by age and sex, Australian states and territories. Canberra: ABS, 1999. (Catalogue No. 3201.0.) Available at: http://www.abs.gov.au/ausstats/abs@.nsf/70e266437a51906dca256820001438b9/f01739c0704ed991ca2569b90082e723!OpenDocument (accessed Jul 2005).
- 13. Kristiansen M, Aggerbeck H, Heron I. Improved ELISA for determination of anti-diphtheria and/or anti-tetanus antitoxin antibodies in sera. APMIS 1997; 105: 843-853.
- 14. von Hunolstein C, Aggerbeck H, Andrews N, et al. European Sero-Epidemiology Network: standardisation of the results of diphtheria antitoxin assays. Vaccine 2000; 18: 3287-3296.
- 15. National Health and Medical Research Council. The Australian immunisation handbook. 8th ed. Canberra: Australian Government Department of Health and Ageing, 2003.
- 16. de Melker HE, van den Hof S, Berbers GA, et al. A population-based study on tetanus antitoxin levels in The Netherlands. Vaccine 1999; 18: 100-108.
- 17. Trinca JC. Immunity to tetanus in Victoria, 1973. Med J Aust 1974; 2: 595-598.
- 18. Forsell P. Diphtheria immunity in Victoria. Med J Aust 1972; 1: 1023-1026.
- 19. Bowie C. Tetanus toxoid for adults — too much of a good thing. Lancet 1996; 348: 1185-1186.
- 20. de Benoist AC, White JM, Efstratiou A, et al. Imported cutaneous diphtheria, United Kingdom. Emerg Infect Dis 2004; 10: 511-513.
- 21. Bisgard KM, Hardy IR, Popovic T, et al. Respiratory diphtheria in the United States, 1980 through 1995. Am J Public Health 1998; 88: 787-791.
- 22. World Health Organization. Diphtheria epidemic in Europe: emergency response. Report on a WHO Meeting; 1993 July; St Petersburg, Russia. WHO Report No. EUR/ICP/EPI 038 Rev 1.
- 23. National Health and Medical Research Council. The Australian Immunisation Handbook. 7th ed. Canberra: AGPS, 2000.
- 24. Olander RM, Wuorimaa T, Kayhty H, et al. Booster response to the tetanus and diphtheria toxoid carriers of 11-valent pneumococcal conjugate vaccine in adults and toddlers. Vaccine 2001; 20: 336-341.
- 25. Hoppenbrouwers K, Roelants M, Ethevenaux C, et al. The effect of reconstitution of an Haemophilus influenzae type b-tetanus toxoid conjugate (PRP-T) vaccine on the immune responses to a diphtheria-tetanus-whole cell pertussis (DTwP) vaccine: a five-year follow-up. Vaccine 1999; 17: 2588-2598.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.